Product Description
Mechanisms of Action: NF-KB Inhibitor,GK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Eurofarma Laboratorios
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Lichen Planus, Oral|Back Pain|Osteoarthritis, Knee|Low Back Pain|Hyperlipidemia|Osteoarthritis
Phase 3: Osteoarthritis|Osteoarthritis, Knee|Irritable Bowel Syndrome|Arthritis, Rheumatoid|Arthralgia
Phase 2: Severe Acute Malnutrition|Arthralgia|Osteoarthritis|Breast Cancer|Osteoarthritis, Knee|Periodontal Pocket|Type 2 Diabetes|Depressive Disorder
Phase 1: Osteoarthritis, Knee|Insulin Resistance|Inflammation|Chronic Periodontitis|Overweight|Obesity|Small Cell Lung Cancer|Non-Small-Cell Lung Cancer|COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2400085486 | N/A |
Not yet recruiting |
Osteoarthritis, Knee |
2026-06-14 |
|
| ChiCTR2400084996 | N/A |
Not yet recruiting |
Osteoarthritis |
2026-03-31 |
|
| ChiCTR2400085577 | N/A |
Recruiting |
Osteoarthritis, Knee |
2025-12-31 |
|
| ChiCTR2300078371 | N/A |
Not yet recruiting |
Osteoarthritis, Knee |
2025-12-31 |